mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Current Jobs

Health Policy Manager
Location: Nationwide

Oncology Hospital Specialist
Location: South and South West of England

Boehringer-Ingelheim reveals EC approval of Micardis

Posted on 30/11/2009 in Pharmaceutical Company Product News

Boehringer-Ingelheim has revealed that Micardis (telmisartan) - its treatment for the reduction of cardiovascular (CV) morbidity risk - has been approved by the European commission (EC).

It has been indicated for use in patients suffering from manifest atherothrombotic CV disease or type 2 diabetes with documented target organ damage.

The EC's recommendations have been made following the results of clinical trials which showed that Micardis has the potential to prevent one in five serious CV events.

"These approvals clearly demonstrate the unique treatment option that Micardis now provides to both physicians and patients as the only medication in the ARB class to provide proven CV protection," explained professor Giuseppe Mancia, chairman of the department of clinical medicine at the University of Milan.

In other Boehringer-Ingelheim news, the firm announced earlier this month that its drug flibanserin passed the phase III trials stage and was shown to ease the stresses associated with hypoactive sexual desire disorder.

Other news stories from 30/11/2009

Read more in the Zenopa News Archive

How this news is generated

Claire
Account Manager
for this opportunity

01494 818 025
(Mon to Fri 0830 to 1800 hours)
claire@zenopa.com

Latest News

Boehringer Ingelheim publishes dabigatran etexilate trial data

Boehringer Ingelheim to acquire SSP

Boehringer Ingelheim piglet castration product approved in EU

Boehringer Ingelheim to collaborate with Priaxon

Boehringer Ingelheim begins ovarian cancer trial

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use